Rep. Lisa C. McClain Sells Off Shares of AstraZeneca PLC (NASDAQ:AZN)

Representative Lisa C. McClain (R-Michigan) recently sold shares of AstraZeneca PLC (NASDAQ:AZN). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in AstraZeneca stock on October 31st. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

AstraZeneca Stock Performance

NASDAQ:AZN traded up $0.08 during trading on Wednesday, reaching $93.32. The company’s stock had a trading volume of 4,656,008 shares, compared to its average volume of 5,159,645. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $94.02. The firm has a market cap of $289.43 billion, a price-to-earnings ratio of 35.08, a price-to-earnings-growth ratio of 1.52 and a beta of 0.34. The firm has a 50 day moving average of $83.58 and a 200-day moving average of $77.23. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.05. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The company had revenue of $15.19 billion during the quarter, compared to analyst estimates of $14.75 billion. During the same quarter in the prior year, the business earned $2.08 earnings per share. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. Research analysts expect that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday, October 16th. Finally, Jefferies Financial Group assumed coverage on shares of AstraZeneca in a research note on Monday, October 27th. They issued a “buy” rating for the company. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in AZN. NewSquare Capital LLC boosted its stake in AstraZeneca by 149.3% during the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after buying an additional 218 shares during the period. Triumph Capital Management purchased a new position in shares of AstraZeneca during the third quarter worth about $25,000. Richardson Financial Services Inc. increased its position in shares of AstraZeneca by 59.8% in the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock worth $28,000 after purchasing an additional 149 shares during the last quarter. Costello Asset Management INC purchased a new stake in AstraZeneca in the first quarter valued at approximately $29,000. Finally, Rakuten Investment Management Inc. bought a new stake in AstraZeneca during the third quarter valued at approximately $31,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.